Recommendations for Addressing Harm-Benefit Analysis and Implementation in Ethical Evaluation - Report from the AALAS-FELASA Working Group on Harm-Benefit Analysis - Part 2

Kathy Laber; Christian E Newcomer; Thierry Decelle; Jeffrey I Everitt; Javier Guillen; Aurora Brønstad

doi:10.1177/0023677216642397

Recommendations for Addressing Harm-Benefit Analysis and Implementation in Ethical Evaluation - Report from the AALAS-FELASA Working Group on Harm-Benefit Analysis - Part 2

Lab Anim. 2016 Jun;50(1 Suppl):21-42. doi: 10.1177/0023677216642397.

Authors

Kathy Laber¹, Christian E Newcomer², Thierry Decelle³, Jeffrey I Everitt⁴, Javier Guillen⁵, Aurora Brønstad⁶

Affiliations

¹ Chief, Comparative Medicine Branch, NIEHS/NIH, Research Triangle Park, NC, USA kathy.laber@nih.gov.
² AAALAC International, Frederick, MD, USA.
³ Chief Veterinary Officer, Sanofi, Marcy l'Etoile, France.
⁴ Department of Laboratory Animal Science, GlaxoSmithKline, Research Triangle, Park, NC, USA.
⁵ AAALAC International, Pamplona, Spain.
⁶ University of Bergen, Department of Clinical Medicine, Bergen, Norway.

Abstract

International regulations and guidelines strongly suggest that the use of animal models in scientific research should be initiated only after the authority responsible for the review of animal studies has concluded a well-thought-out harm-benefit analysis (HBA) and deemed the project to be appropriate. The AALAS-FELASA working group on HBA has performed a literature review and based on this review, proposed a method for HBA. Examples of the working group's approach are included in this report.

Keywords: ethical review; harm–benefit.

Publication types

Review

MeSH terms

Animal Experimentation / ethics*
Animal Welfare / standards*
Animals
Animals, Laboratory
Guidelines as Topic / standards*
Humans
Risk Assessment
Risk Factors

Grants and funding

Z99 ES999999/Intramural NIH HHS/United States